← Back
Data updated: Jul 17, 2026
ST JOHN PHARM
Generics Pharmaceuticals
ST JOHN PHARM is a generic drug manufacturer with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Aug 17, 2026 — Iberdomide + daratumumab/dexamethasone
30d ST JOHN PHARM's Key Drugs
ST JOHN PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
ST JOHN PHARM's Recent FDA Approvals
New NDA/BLA approvals for ST JOHN PHARM over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ST JOHN PHARM's Therapeutic Areas
Disease areas where ST JOHN PHARM has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ST JOHN PHARM Pipeline Snapshot
Active clinical trials for ST JOHN PHARM across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-10-16
- Latest
- 2018-10-16
- Applications
- 1